TCGA-C8-A26Z-01A-11R-A16F-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 16
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- ESTROGEN_RESPONSE_EARLY+0.260
- DNA_REPAIR+0.230
- PANCREAS_BETA_CELLS+0.190
- PEROXISOME+0.190
- OXIDATIVE_PHOSPHORYLATION+0.150
- UNFOLDED_PROTEIN_RESPONSE+0.150
- MITOTIC_SPINDLE+0.140
- ESTROGEN_RESPONSE_LATE+0.130
- MYC_TARGETS_V1+0.130
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.580
- INTERFERON_ALPHA_RESPONSE-0.560
- IL6_JAK_STAT3_SIGNALING-0.510
- INTERFERON_GAMMA_RESPONSE-0.510
- INFLAMMATORY_RESPONSE-0.480
- TNFA_SIGNALING_VIA_NFKB-0.390
- KRAS_SIGNALING_UP-0.360
- COMPLEMENT-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- KRAS_SIGNALING_DN-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.902 |
| 2 | TCGA-E2-A156-01A-11R-A12D-07 | — | B | 0.885 |
| 3 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.850 |
| 4 | TCGA-E9-A1R7-01A-11R-A14M-07 | — | B | 0.848 |
| 5 | TCGA-D8-A1XR-01A-11R-A14M-07 | — | B | 0.845 |
| 6 | TCGA-EW-A1OX-01A-11R-A144-07 | — | B | 0.837 |
| 7 | TCGA-E9-A1RC-01A-11R-A157-07 | — | B | 0.833 |
| 8 | TCGA-BH-A0E7-01A-11R-A034-07 | — | B | 0.833 |
| 9 | sclc2008_S40.txt | — | cohortSC | 0.833 |
| 10 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |